Report on the risk assessment of N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) in the framework of the Council Decision on new psychoactive substances

Introduction

This publication presents the data and findings of the risk assessment on N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 21 March 2018. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 27 September 2018, the Council decided that cyclopropylfentanyl should be subject to control measures across the Member States.

Download as PDF

Table of contents

  • Foreword
  • EMCDDA actions on monitoring and responding to new drugs
  • EMCDDA‒Europol Joint Report on N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl): a summary
  • Risk Assessment Report of a new psychoactive substance: N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl)
  • Annex 1: Technical report on N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl)
  • Participants of the risk assessment meeting
Top